Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Dolutegravir and Truimeq approved in England: London guidelines updated

On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

Published
14 January 2015
From
HIV i-Base
New HIV Gene Therapy Shows Promise in Mice

Researchers were able to replicate the functional cure of HIV that was seen in the "Berlin patient" in a mouse model, according to a study conducted at the University of California, Davis.

Published
14 January 2015
From
The Body Pro
Study uncovers new ground about when to start HIV therapy

A major question that has recurred since the availability of potent combination anti-HIV therapy (commonly called ART or HAART) is when this therapy should be initiated to ensure the optimal health of HIV-positive people. New research has revealed that early therapy may be highly beneficial.

Published
13 January 2015
From
CATIE
Dolutegravir/abacavir/lamivudine: considerable added benefit for treatment-naive adults with HIV

Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. The Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.

Published
12 January 2015
From
The Institute for Quality and Efficiency in Health Care
Argos tanks as its HIV immunotherapy flunks Phase II

The treatment, AGS-004, is a personalized immunotherapy designed to train patients' T cells to better attack HIV. In a placebo-controlled Phase IIb trial, AGS-004 missed its primary endpoint of significantly lowering viral load among chronically infected patients.

Published
12 January 2015
From
FierceBiotech
I Am the Berlin Patient: A Personal Reflection

My name is Timothy Ray Brown and I am the first person in the world to be cured of HIV.

Published
08 January 2015
From
AIDS Research and Human Retroviruses
First Year After HIV Infection Is Key Window for Treatment Start

Waiting to start HIV treatment until 12 months after the estimated date of seroconversion decreases the likelihood of restoring the immune system.

Published
07 January 2015
From
AIDSMeds
Zimbabwe: Govt introduces new HIV treatment

The Zimbabwean government is with effect from this month switching all people on HIV treatment to a new one of one tablet per day from the previous three pills to make it easier for patients not to default on taking medication. The new single tablet has a combination of three drugs (Tenofovir/Lamivudine/Efavirenz TLE), a departure from the previous complicated treatment of three different tablets namely Tenofovir, Lovovidine and Nevirapine (TLN).

Published
07 January 2015
From
NewZimbabwe.com
Elite controllers may pay a high price for their low viral load

About one in 200 people with HIV maintains an undetectable viral load and high CD4 counts without having to take antiretroviral therapy (ART). These so-called ‘elite controllers’

Published
07 January 2015
By
Gus Cairns
US guidelines on prevention with people living with HIV now emphasise engagement with care, HIV treatment and social factors

The American public health agency, the Centers for Disease Control and Prevention (CDC) has published new recommendations on the HIV prevention interventions and advice that should

Published
05 January 2015
By
Roger Pebody

Filter by country